Skip to Main Content

In an unusual move, a Moscow court has granted a compulsory license to a domestic company that plans to make and sell a version of a best-selling Celgene (CELG) medicine. And tucked into the decision was a reference to promoting public health, a stance that was reiterated this week by a Russian delegate to a United Nations forum on patents, according to one attendee.

At issue is Revlimid, a blockbuster cancer drug that generated $8.2 billion in worldwide sales in 2017 for Celgene. The biotech last year filed a lawsuit against a Russian company called Nativa to ban production and sales of a copycat version. But last month an arbitration court sided with Nativa, which plans to sell its version for 20 percent to 66 percent less, depending upon the dose, a company spokeswoman wrote us.


A Celgene spokesman wrote us that the biotech appealed the decision and so the license will not go into effect until the matter is resolved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.